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Abstract
Mycobacterium tuberculosis is a pathogen causing tuberculosis (TB) a spectrum of disease
including acute and asymptomatic latent stages. Identifying and treating latently-infected
patients constitutes one of the most important impediments to TB control efforts. Those indi-
viduals can remain undiagnosed for decades serving as potential reservoirs for disease
reactivation. Tests for the accurate diagnosis of latent infection currently are unavailable.
HspX protein (α-crystallin), encoded by Rv2031c gene, is produced in vitro by M. tuberculo-
sis during stationary growth phase and hypoxic or acidic culture conditions. In this study,
using standard, and Luminex xMAP® bead capture ELISA, respectively, we report on detec-
tion of anti-HspX IgG and IgM antibodies and HspX protein in sera from acute and latent TB
patients. For the antibody screen, levels of IgG and IgM antibodies were similar between
non-infected and active TB patients; however, individuals classified into the group with latent
TB showed higher values of anti-HspX IgM (p = 0.003) compared to active TB patients.
Using the bead capture antigen detection assay, HspX protein was detected in sera from
56.5% of putative latent cases (p< 0.050) compared to the background median with an
average of 9,900 pg/ml and a range of 1,000 to 36,000 pg/ml. Thus, presence of anti-HspX
IgM antibodies and HspX protein in sera may be markers of latent TB.
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Introduction
Tuberculosis (TB) is a bacterial disease primarily caused by infection with Mycobacterium
tuberculosis. In 2014, an estimated 9.6 million people developed TB and 1.5 million died from
the disease (including 400,000 deaths among HIV-positive individuals). In addition, approxi-
mately 480,000 multidrug resistant TB (MDR-TB) cases were reported [1]. Until a protective
TB vaccine is developed, accurate diagnosis and effective treatment are the most useful tools
available for controlling this disease.
Latent TB infection (LTBI) is defined as a state of persistent immune response to stimula-
tion by M. tuberculosis antigens without evidence of clinically manifested active TB [2, 3]. Per-
sons with LTBI have negative bacteriological tests and the presumptive diagnosis is based on a
positive result of either a skin (tuberculin skin test, TST) or blood (interferon-gamma release
assay, IGRA) test indicating an immune response to M. tuberculosis infection. There are treat-
ment regimens that can reduce but not eliminate the risk of reactivation disease in individuals
with LTBI, but such prophylactic therapy involves taking antibiotics for up to 9 months, and
carries a small risk of serious, or even fatal, side-effects in these TST/IGRA-positive individuals
only suspected of having LTBI. At present, a direct measurement tool for LTBI in humans is
currently unavailable [2, 3], and the inability to identify the population of individuals with
LTBI constitutes a major impediment to TB control efforts [4]. An Institute of Medicine report
concluded that the development of new diagnostics that can distinguish the truly infected indi-
viduals from those who are exposed but self-cured/false positive will be the key to ultimately
eliminating TB [5].
Proteins expressed under stress are ubiquitous in nature and they play an important role in
helping bacterial cells to survive under extreme conditions. It is hypothesized that the primary
location for latent M. tuberculosis bacilli is the granuloma, and within these structures, the bac-
teria are exposed to adverse conditions including hypoxic stress, low pH, hydrolytic enzymes,
toxic fatty acids and reactive oxygen radicals. To survive, bacilli upregulate stress-response
proteins including chaperones and transport proteins associated with pH control, metabolite
movement, and lipid metabolism [6–9]. The M. tuberculosis Rv2031c gene encodes HspX
(also known as α-crystallin, Acr, or the 16-kDa antigen) which is expressed during stationary
growth, under hypoxia, and low pH, similar to conditions present within areas of some granu-
lomas [10]. HspX may be an important element of M. tuberculosis replication control in the
granuloma since its over-expression inhibits M. tuberculosis growth [11–13].
The use of a serodiagnostic test for TB was analyzed by Limongi et al. [14], who reported
that specific anti-HspX IgA in pleural fluid samples was useful to discriminate between pleural
effusion due to TB and other pulmonary disease. Similarly, detection of IgG, IgA, and IgM
antibodies against the M. tuberculosis16-kDa antigen were evaluated by ELISA as a diagnostic
tool in sera from TB patients and healthy subjects [15]. A combination of the three isotypes
gave a sensitivity of 83% and specificity of 93% while precipitated circulating immune com-
plexes of these antibodies improved the sensitivity to 97.5%. Interestingly, Steingart et al. [16]
reported a commercial antibody detection test for the diagnosis of pulmonary TB that detects
IgG against the M. tuberculosis 38-kDa and 16-kDa antigens, but does not include the detec-
tion of IgM.
Alternatively, two groups have reported that they are examining direct detection of M.
tuberculosis antigens released into body fluids, however, those tests target abundant non-spe-
cific mycobacterial cell wall components: lipoarabinomannan (LAM) in urine [17, 18]. The
relative reluctance of investigators to employ the detection of a low abundance secreted protein
as a diagnostic is due to uncertainty as to what specific antigens are most appropriate, and the
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expectation that these factors may only be present in very low amounts in serum, especially in
the case of LTBI.
As described, HspX is produced exclusively during periods of bacterial stress, including sur-
vival within granulomas [19]. In that study, naphthol red-tagged anti-HspX monoclonal anti-
body highlighted the presence of HspX protein on bacterial outer membranes within guinea
pig early granulomas (3 weeks after infection) and later granulomas (10 weeks post-infection).
Based on these and other unpublished studies, it was expected that this protein would be pres-
ent in patient sera in picogram/ml to femtogram/ml concentrations; theoretically detectable
amounts by ultra-sensitive detection systems. In this study, we report on successful detection
of anti-HspX antibodies and HspX protein in LTBI patient sera, and statistically determine
diagnostic potential.
Materials and methods
Ethics statement
The present study and the consent procedures were specifically approved by the Review Board
of the National Research Commission of Instituto Mexicano del Seguro Social with approval
number: R-2011-1906-41 in Mexico and The University of Georgia, Emory University and the
DeKalb County, Georgia, and Board of Health Institutional Review Boards in United States of
America.
Study populations
Anti-HspX antibody detection ELISA. Serum samples of 98 adults were provided by the
Center for Research, Prevention and Treatment of Respiratory Infections (CIPTIR) Hospital
Universitario "Dr. Jose´ Eleuterio Gonza´lez", in Monterrey, Mexico. All of the individuals
signed an informed consent before sampling. Patients were classified into four groups: Group
1: active TB, positive tuberculin test (PPD+,(induration greater than 10 mm), positive inter-
feron-gamma release assay (QuantiFERON1, QFT+), positive smear test and positive micro-
organism culture (n = 28); Group 2: LTBI, PPD+, contact with active TB persons (COMBE+),
with or without history of TB in the family (n = 30); Group 3: uninfected individuals, negative
tuberculin test (PPD-) and absence of symptoms (n = 15); and Group 4: unknown status,
inconsistent results between tests (n = 25).
Luminex xMAP1HspX protein detection ELISA. Sixty adults were enrolled at the
DeKalb County (Georgia, USA) Board of Health Refugee Program/Refugee Clinic, and TB
and LTBI clinics. Students entering the Emory University School of Medicine were a source of
uninfected controls. All individuals signed an informed consent before sampling. However,
unlike the anti-HspX antibody detection ELISA, patients were classified into only three
groups: Group 1: active TB, positive tuberculin test (PPD+, induration greater than 10 mm) or
positive interferon-gamma release assay (QuantiFERON1, QFT+), positive smear test and
positive microorganism culture (n = 13); Group 2: LTBI, PPD+, contact with active TB persons
(COMBE+), with or without history of TB in the family (n = 23); and Group 3: uninfected
individuals, negative tuberculin test (PPD-) and absence of symptoms (n = 24).
All blood samples (10 ml) were collected by venipuncture, allowed to clot at room tempera-
ture (20–25˚C) and then centrifuged according to the clinical and Laboratory Standards Insti-
tute (CLSI-Approved Standard-Procedures for the collection of Diagnostic Blood Specimens
by Venipuncture, H3-A4, 1998). The serum was separated and frozen (-20˚C) until analysis
was performed.
HspX in tuberculosis patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0181714 August 16, 2017 3 / 13
Construction of recombinant plasmid pET-23b(+)hspX
The sequence of Rv2031c (TB database: GB: AL123456) was used to design primers. The
sequences for HindIII and XhoI cleavage sites were added to the 50 end of forward PHspXF
(AAGCTTATGGCCACCACCCTTCCC) and reverse PHspXR (CTCGAGGTTGGTGGACCGGAT
CT) primers, respectively (bold letters correspond to restriction sites). The sequence encoding
for M. tuberculosis hspX gene (Rv2031c) was PCR amplified from the M. tuberculosis H37Rv
genome using a hot-start enzyme (Platinum1Taq DNA Polymerase) and subcloned into a C-
terminal His-tag pET23b(+) vector (Novagen) using HindIII and XhoI restrictions sites follow-
ing manufacturer instructions. Competent Escherichia coli BL21 (DE3)pLysS (Promega) was
transformed with the plasmid containing the hspX gene. Recombinant bacteria were grown in
LB broth for 1.5 hr at 37˚C with shaking and subsequently 100 μl of culture were plated on LB
agar (Invitogen, Carlsbad, CA) with ampicillin (100 μg/ml) (Amp100) and chloramphenicol
(50 μg/ml) (Cam50). Subsequently, the pET-23b(+)hspX vector was purified using Wizard1-
Plus SV Minipreps ADN Purification System (Promega Corporation, Madison, WI) with a
subsequent sequence confirmation step.
Production and purification of the recombinant HspX protein
Recombinant HspX protein was purified from BL21 (DE3) pLysS cells transformed with
pET23b(+)hspX. Briefly, a recombinant clone was grown overnight in 3.5 ml of LB broth with
Amp100 and Cam50 with shaking (200 rpm). Three milliliters of bacterial suspension were
inoculated into 300 ml of fresh LB broth with Amp100 and Cam50 and incubated at 37˚C with
shaking (200 rpm) to OD600 = 0.5. The culture was IPTG-induced (final concentration of 1
mM) for 3 hr with shaking (200 rpm) at 37˚C. Purified protein was obtained using affinity
chromatography with a Ni+ binding column and dialysis. Each purification step was con-
firmed on a 14% SDS-PAGE. Final concentration of purified recombinant HspX was 0.66 mg/
ml.
Native HspX protein, obtained from BEI Resources, has a predicted molecular mass of
16-kDa, while the rHspX has a predicted molecular mass of approximately 20-kDa due to the
added upstream T7 tag and downstream 6-His tag.
Detection of HspX recombinant protein by western blot
Purified protein (0.36 mg/ml) was resolved by 14% SDS-PAGE. Subsequently, proteins were
transferred to a nitrocellulose membrane at 35V and 4˚C overnight (Mini Trans-Blot Cell
(Bio-Rad). The membrane was incubated with blocking buffer (PBS 1X, 5% skim milk, 0.1%
Tween 20) overnight with orbital shaking (4˚C, 150 rpm), and washed 5X with PBS-T 1X (PBS
1X, 0.1% Tween 20). The membrane was incubated with 50 ml of a 1:100 dilution of anti-
HspX monoclonal antibody (clone IT-20 NR-13607, from BEI Resources) as primary antibody
at 4˚C with shaking (150 rpm) overnight. After 5X washes (10 min each) with 1X PBS-T, 50 ml
of the polyclonal secondary antibody (1:1500 dilution) goat anti-mouse IgG conjugated with
HRP (Abcam, Cambridge, UK) was added and incubated for 2 hr at 4˚C followed by 5X
washes with 1X PBS-T. Finally, protein was detected by chemiluminescence using the Super-
Signal1West Pico Chemiluminiscent Substrate (Pierce Biotechnology, Rockford, IL) following
manufacturer´s recommendations.
Analysis of cross-reacting M. tuberculosis HspX homologs
An in silico analysis was performed to identify proteins homologous to M. tuberculosis HspX.
The resulting protein sequences were compared using program DNASTAR to obtain the
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percentage of similarity and divergence with HspX (S1 and S2 Tables). Mycobacterial genomes
selected for analysis were: M. tuberculosis H37Rv, M. bovis BCG, M. bovis, M. scrofulaceum,
M. kansasii, M. intracellulare, M. smegmatis, M. rhodesiae, M. fortuitum, M. vaccae, M. avium,
and M. tuberculosis Beijing genotype. Bacteria were grown on 30 ml Middlebrook 7H9 +
OADC broth during 20 days at 37˚C in sealed tubes to favor oxygen depletion conditions [8];
except M. tuberculosis Beijing, cultures were harvested after 7 days. Harvested cells were resus-
pended in 1 ml of TBS (100 mM, pH 7.4, 0.5% Triton X-100 and EDTA-free protease inhibitor
cocktail (Boehringer Manheim, Germany) and lysed in a FastPrep1 instrument using 3 cycles
of 45 sec at speed 5 with cooling on ice between runs. Cross-reaction was analyzed by western
blot as described previously using 0.36 mg/ml of protein of each lysate.
Detection of IgG and IgM antibodies against HspX protein in TB patient
sera by ELISA
Microplates (96-well) coated with nickel (Thermo Scientific Nunc Immobilizer Nickel—Che-
late, Waltham, MA) were pre-washed 3X (300 μl/well) with PBST (PBS + 0.05% Tween 20 and
covered with 50 μl of 10 μg/ml purified recombinant protein HspX-His previously dissolved in
KCl 0.01 M. Plates were incubated at 4˚C with shaking (450 rpm) overnight. Plates then were
washed 3X with 300 μl PBST and blocked with 300 μl of 5% skim milk for 2 hr, followed by 3
washes with PBST (300 μl ea.). Prepared plates were loaded with 100 μl per well of patient
serum (1:50 dilution in1% skim milk) and incubated at 37˚C for 90 min. After incubation, the
plates were washed with PBST (3 x 300 μl) and 100 μl of secondary antibody-HRP (goat anti-
human IgM at 1:10,000 or anti-human IgG at 1:30,000) (Sigma Aldrich) were added and incu-
bated for 1 hr at 37˚C. Plates were washed again with PBST (3 x 300 μl) and 100 μl of Sigma
Fast OPD solution (Peroxidase substrate, Sigma Aldrich, St Louis, MO) was added to each
well. After 30 min incubation, the reaction was stopped with 50 μl of 3N sulfuric acid. ELISA
absorbance readings at 492 nm were taken using a microplate reader Synergy 2 (BioTek, Inc.,
Winooski, VT).
Detection of HspX protein in TB patient sera by Luminex xMAP®bead
capture ELISA
A collection of 30 mouse anti-M. tuberculosis HspX (Gene Rv2031) monoclonal antibodies,
including IT-20 (NR-13607), IT-49 (NR-13814), and IT-50 (NR-13815) obtained from BEI
Resources NIH NIAID, were screened for optimal sensitivity and specificity in a Luminex
xMAP1/Magpix (Luminex corp, Austin, TX) bead-capture ELISA system [20, 21]. This sys-
tem was used to further enhance detection sensitivity compared to standard ELISA. The
selected antibody pair, IT-20 (IgG1κ) and PAC326 (IgG2aκ) (kindly provided by D. Bagarrozi,
CDC), generated against rHspX protein, were found to produce strong reactivity signals with
routine detection of native or rHspX in spiked sera in the 1–10 pg/ml range. Luminex provides
kits of amine-reactive paramagnetic fluorescent microspheres magnetized beads and a flow
cytometry assay detection device (Magpix) as an open platform upon which research groups
can develop custom assays using their own reagents. Assay methods recommended by the
manufacturer were employed. Carboxylated beads were activated with an xMAP Antibody
Coupling Kit (Luminexcorp, Austin, TX) and covalently conjugated with anti-HspX antibody,
clone IT-20, according to manufacturer’s instructions. Capture antibody-coated beads were
reacted with samples or rHspX-spiked standards and subsequently incubated with anti-HspX
reporter antibody, clone PAC326, which was previously biotinylated with an EZ-Link Micro
NHS-PEO4-Biotinylation Kit (Pierce Biotechnology, Rockford, IL). Beads were then devel-
oped with PhycoLink1 Streptavidin-R-Phycoerythrin (ProZyme, Hayward, CA). Data were
HspX in tuberculosis patients
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collected on a Magpix instrument using xPONENT v.4.2 (Luminexcorp) and analyzed with
Milliplex1 Analyst software, v.5.1 (EMD Millipore, Billerica, MA).
Statistical analysis
Anti-HspX antibody detection ELISA. Measures of central tendency and variability were
calculated from the absorbance values of anti-HspX IgG and IgM. The normality test K2
D’Agostino-Pearson was used to assess data. Differences between groups were analyzed by the
Kruskal-Wallis and Dunn’s tests. To determine a cutoff value to distinguish different stages of
TB infection Receiver Operating Characteristic (ROC) curve analysis using SPSS version 11.0
was used. All tests were calculated with a 0.05 of significance level and corrected using the Bon-
ferroni method (0.0083).
Luminex HspX protein detection ELISA. Normality test using Shapiro-Wilk statistical
analysis was p< 0.050. Further nonparametric Kruskal-Wallis One Way Analysis of Variance
(ANOVA) on Ranks, with all pairwise multiple comparison procedures using Dunn’s Method
showed p< 0.05 for LTBI vs active TB groups, p<0.05 for control vs active groups, and
p>0.05 for LTBI vs uninfected groups.
Results
Immunodetection of rHspX
To examine potential cross-reactivity with homologous proteins from related bacteria, whole
cell lysates from strains listed in Materials and methods section were prepared and western
blot analysis performed. Anti-HspX monoclonal antibodies IT-20 only recognized the recom-
binant HspX protein and HspX from M. tuberculosis strain H37Rv lysate (S3 and S4 Figs). The
Luminex bead capture assay detected no HspX protein in stationary phase culture superna-
tants from Mycobacterium species possessing protein sequences similar to M. tuberculosis,
including M. rhodesiae, M. kansasii, M. fortuitum and M. vaccae. Interestingly, no cross reac-
tivity was detected in culture supernatants from M. bovis BCG. M. tuberculosis Beijing har-
vested in log phase did not produce detectable HspX.
Detection of IgG and IgM antibodies against HspX protein in serum of
patients by ELISA
Anti-HspX IgG and IgM antibodies were detected in sera from patients classified as active TB,
LTBI, unknown status, or uninfected individuals. For the antibody ELISA, levels of IgG and
IgM antibodies were similar between non-infected and active TB patients. However, the level
of reaction by the IgM antibodies was statistically higher (p = 0.003) in individuals classified
with LTBI versus individuals with diagnosed active TB (Fig 1A). While IgG antibodies against
HspX were detected in sera from all groups examined, there were no significant differences in
level of reaction among the groups (Fig 1B).
Separating recently infected LTBI (rLTBI) patients from all other LTBI patients according
to Rabahi et al. [22], significant differences between IgM antibodies (Fig 2A) or IgG (Fig 2B)
from individuals with rLTBI compared to all other groups was observed. ROC curve analysis
based on OD492 values produced a cutoff point of 1.7 for IgG antibodies and a cutoff of 1.2 for
IgM antibodies to identify an rLTBI patient.
Detection of HspX protein in patient sera by ELISA
PBS and pooled normal human sera (NHS) were spiked with varying concentrations of
rHspX. Using ECL chemiluminescent ELISA, detection limits of 10 pg/ml in PBS and
HspX in tuberculosis patients
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100 pg/ml in NHS were attained. Subsequently, serum samples were assessed from 5 human
patients with recently diagnosed active TB disease and prior to initiation of anti-mycobacterial
therapy, 5 TST-positive suspected LTBI cases, and 5 healthy TST-negative individuals. In this
study, 4 of 5 human serum samples from individuals with active TB disease were positive while
uninfected controls were below detectable levels. In the suspected LTBI group, 2 of 5 samples
tested positive.
Detection of HspX protein in patient sera by Luminex xMAP® bead-
capture ELISA
Twenty-four TST negative control sera were screened for HspX and a median level of 470 pg/
ml was detected (Fig 3). Of the 23 putative samples from LTBI patients, 13 of 23 samples
(56.5%) scored greater than 1 standard deviation above the background median with an
average of 9,900pg/ml and a range of 1,000 to 36,000 pg/ml. Zero of 13 samples from patients
with culture-confirmed active disease cases contained levels of HspX above the background
median.
Fig 1. Detection of anti- HspX IgM and IgG in human sera by ELISA. Optical densities (492 nm) of IgM (A)
or IgG antibodies (B) against recombinant HspX protein in individuals classified as active TB, unknown,
uninfected and LTBI.
https://doi.org/10.1371/journal.pone.0181714.g001
Fig 2. ELISA detection of anti-HspX IgM and IgG in serum of re-classified individuals. Optical densities
(492 nm) of IgM (A) or IgG antibodies (B) against recombinant HspX in persons classified as active TB,
unknown, uninfected, LTBI or rLTBI.
https://doi.org/10.1371/journal.pone.0181714.g002
HspX in tuberculosis patients
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Discussion
The goal of these studies was to determine the sensitivity and specificity of diagnostic
approaches based upon the direct detection of antibodies against M. tuberculosis latency-asso-
ciated alpha-crystallin (HspX) protein or upon the detection of the HspX protein itself in sera
from individuals with suspected latent TB infection (LTBI).
Successful detection and treatment of individuals with LTBI constitutes a major impedi-
ment of worldwide TB control efforts. Although treatments for LTBI may exist, there currently
are no specific diagnostics for the identification of cases in order to assess therapeutic efficacy;
the lack of suitable biomarkers for mycobacterial latency is the major shortcoming of this
effort. As a first step towards development of a LTBI diagnostic test based on targeting specific
biomarkers, we present data examining detection of the M. tuberculosis HspX protein in
patient sera. This secreted product belongs to the alpha crystallin superfamily of small heat
shock stress proteins [23]. Investigators have referred to HspX as a largely restricted protein in
individuals with LTBI [24]. In the present study, IgG and IgM antibodies produced against the
HspX protein, and the protein itself were separately assayed in sera from confirmed active
cases, suspected LTBI patients, and uninfected healthy controls.
Rabahi et al. [22] studied the humoral response against HspX and GlcB proteins from M.
tuberculosis in health care workers, dividing population into three groups according to TST
results: uninfected (negative PPD, previous LTBI (positive PPD) and recent LTBI (positive
PPD conversion within one year). They found no differences in levels of IgG and IgM antibod-
ies detected against both proteins in all three groups of individuals. However, the mean values
for anti-HspX IgM were significantly higher among health care workers previously infected
compared to uninfected controls, suggesting a possible role for this antigen in identifying
recent LTBI patients. Our results showed similar ELISA values for anti-HspX IgG and IgM in
Fig 3. Scatter plot of HspX detection in clinical TB groups by Luminex bead-capture ELISA. Median for
each group: uninfected 470 pg/ml, LTBI 860pg/ml and active TB 40 pg/ml. Normality test using Shapiro-Wilk
statistical analysis was p < 0.050. Further nonparametric Kruskal-Wallis One Way Analysis of Variance
(ANOVA) on Ranks, with all pairwise multiple comparison procedures using Dunn’s Method showed p < 0.05
for LTBI versus active TB groups, p < 0.05 for uninfected versus active groups, and p > 0.05 for LTBI versus
uninfected groups.
https://doi.org/10.1371/journal.pone.0181714.g003
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sera from LTBI patients versus active TB, and in LTBI patients versus uninfected and
unknown status groups. However, when we reclassified the groups to discriminate between
active TB and LTBI, including recent LTBI (rLTBI) as suggested by Rabahiet al. [22], we found
a significant difference in IgG and IgM levels between individuals with rLTBI and all the other
groups. The ROC analysis shows sensitivity and a specificity of 100% with a cut off 1.7 for IgG
and 1.2 for IgM (Fig 2). Interestingly, the recent-LTBI subgroup included only health care
workers with continuous exposure to M. tuberculosis bacilli or its antigens. These results agree
with the observations by Rabahi et al. [22] and support the idea of assaying for anti-HspX anti-
bodies as a marker to identify recent LTBI.
Development of the antigen detection assay required the initial screen of several dozen
anti-HspX monoclonal antibodies and the subsequent identification of the optimal capture
and detection pair for use in the Luminex xMAP1bead-capture ELISA system. In our study,
13 of 23 TST-positive suspected LTBI cases (56.5%) scored one standard deviation above the
median of the uninfected control population for the presence of serum HspX. The size of the
error bar in Fig 3 and thus the variation in detected antigen level among the suspected LTBI
patients was expected, confirming the hypothesis that LTBI is not a single stage of disease, but
a spectrum, and demonstrating more clearly that the TST and IGRA tests cannot accurately
diagnose it. These data provided support for the implementation of a second larger ongoing
trial. Additionally, in the preliminary experiment, it was observed that 4 of 5 sera from individ-
uals with culture-positive active infections contained measurable HspX. Those data contradict
the results from this most recent study that show all 13 active cases have undetectable HspX
serum levels. Interestingly, samples in the preliminary study were collected prior to the initia-
tion of antimicrobial therapy while all 13 samples used in this Luminex study were from active
disease patients with at least five months of standard therapy. Thus, the antigen detection
assays also may be useful for assessing successful treatment regimens. Studies are being initi-
ated to examine this potential.
A concern regarding the use of HspX as the target for these assays is the potential for cross
reactivity with antigens from closely related species. It was hypothesized that antibodies
against some antigenic sites on the M. tuberculosis HspX protein may share homology with
similar proteins from species of environmental mycobacteria, and that all antigenic sites
should cross-react with the sequence-identical proteins from M. bovis and M. bovis BCG
[25]. To confirm this, immunoblot assays of sera from cattle infections showed reactivity to
three antigens of 26, 22 and 16 kDa; however, the antibody reactivities to the 22 and 16 kDa
proteins could be due to the tuberculin test, because reactivity was evident immediately fol-
lowing tuberculin testing of the animals [26]. In our studies, western blot analysis of cell
lysates from different species of mycobacteria grown under laboratory oxygen depletion con-
firmed the published reports and did not show cross reactivity with the environmental myco-
bacteria, and did not cross react with M. bovis. Only HspX protein from M. tuberculosis
H37Rv cell lysate was positive for the anti-HspX antibodies. It was expected that M. tubercu-
losis Beijing was recognized by anti-HspX antibodies. It is likely that the logarithmic phase
growth conditions rather than the strain itself was responsible for the lack of HspX detection
in our assays [6]. It was encouraging to note that no significant levels of cross reactivity were
detected among the M. tuberculosis-complex species examined. Interestingly, as with the
western blots, cross reactivity between M. tuberculosis and M. bovis (or BCG) HspX proteins
were expected, but not detected. This finding could represent a difference in HspX expres-
sion and secretion pathways between M. tuberculosis and M. bovis in vitro versus in vivo, and
is being actively investigated.
Regarding potential cross reactivity with the BCG vaccine, Geluk et al. [27] found that indi-
viduals infected with or exposed to M. tuberculosis responded well to HspX in the ELISPOT
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assay, while M. tuberculosis-unexposed individuals, including BCG-vaccinated individuals
without any known exposure to M. tuberculosis had significantly lower responses to HspX.
In the same paper, similar results were obtained with BCG-immunized mice, all suggesting
that HspX expression by BCG after vaccination is low and unlikely to produce a significant
immune response against HspX. Rabahi et al. [22] also reported no differences in IgM humoral
responses to HspX in BCG-vaccinated and unvaccinated individuals. Slobbe et al. [28] demon-
strated that BCG bacilli do not remain viable for more than three months post-vaccination,
and it will not secrete HspX in the host. Thus, it is not expected that significant levels of anti-
HspX antibodies or the HspX protein itself would be present in BCG-vaccinated individuals,
and the likelihood of false positives is low. Nonetheless, ongoing studies will attempt to reduce
potential sources of background by multiplexing the assays with additional M. tuberculosis
complex-specific target antibodies and antigens such as for ESAT-6 and M. tuberculosis-spe-
cific cell wall glycans.
In conclusion, these tests have the potential to distinguish between patients that are truly
infected with M. tuberculosis from those who have merely been exposed to non-tuberculous
mycobacteria or have been vaccinated with BCG. It is proposed that both of these tests be
run in tandem since the Luminex test would detect bacterial antigens rather than the host
immune response to the bacillus, and should have the potential to identify M. tuberculosis
infection in subjects with compromised immune systems, such as those with HIV/AIDS.
Concomitantly, the ELISA test detecting the presence of antibody would be more sensitive
and thus identify LTBI cases with lower numbers of infecting bacilli since there likely is a
detection limit for the Luminex assay. The most exciting possibility is that both tests may
identify individuals with LTBI who are at greatest risk of progressing to active disease and
provide a metric for success in treating the identified infection. The assays would provide
quantitative results that should reflect the burden of large numbers of actively-replicating
bacteria, or few latent but viable bacteria capable of reactivating under proper conditions, in
individuals with LTBI. Lastly, to enhance statistical confidence and determine if the assays
can be used to measure therapeutic efficacy, we propose to collect and screen sera from a
larger number of epidemiologically well-defined persons with a high likelihood of LTBI, per-
sons unlikely to have LTBI, and persons with culture positive TB. In this study, we propose to
obtain and screen subsequent monthly samples from individuals in these groups undergoing
treatment for and LTBI.
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